NCT05314270 is a clinical trial of Diagnostic tests in Non-B Non-C Liver Cirrhosis, sponsored by Assiut University.

Who is sponsoring NCT05314270?

NCT05314270 is sponsored by Assiut University.

What drugs are being tested in NCT05314270?

Interventions in NCT05314270: Diagnostic tests.

What condition does NCT05314270 study?

NCT05314270 studies Non-B Non-C Liver Cirrhosis.

Is NCT05314270 still recruiting?

NCT05314270 is currently status unknown. Last updated 6 April 2022.

Last reviewed 2022-04-06 · How we verify

NCT05314270

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Non-B Non-C Liver Cirrhosis in A EL-Rajhi Assuit University Hospital: A Retrospective-Prospective Study

Status unknown Last updated 6 April 2022

What this trial tests

trial testing Diagnostic tests in Non-B Non-C Liver Cirrhosis in 100 participants. Status unknown.

Timeline

1 October 2022

Primary endpoint
1 October 2023

1 November 2023

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 October 2022
Primary completion	1 October 2023
Estimated completion	1 November 2023

Drugs / interventions tested

Diagnostic tests

Conditions studied

Non-B Non-C Liver Cirrhosis — all drugs for Non-B Non-C Liver Cirrhosis →

Sponsor

Assiut University

Who can join

Eligibility, any sex, with Non-B Non-C Liver Cirrhosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To study the etiologies of patients diagnosed as non-B, non-C liver cirrhosis (NBNC-LC). To describe the different patient's outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Diagnostic tests

Trials testing the same drug.

NCT05282342 — Heart Transplant Patients, Health Status and Physical Activity · completed
NCT04828629 — Complications and the Influence of COVID-19 on Myocardial Function and Exercise Capacity · unknown
NCT04802369 — Factors and Prognostic Significance of Impaired Exercise Tolerance in Women Over 40 With Arterial Hypertension · NA · completed
NCT03481712 — Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease 2 · completed

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05314270 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 6 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05314270.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing